Actively Recruiting
The Impact of a Moderate Carbohydrate Diet in Children With Type 1 Diabetes on Hybrid Closed-loop Therapy
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-08-22
28
Participants Needed
1
Research Sites
85 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In the past, carbohydrate restriction was indicated as a treatment for people with type 1 diabetes when exogenous insulin was not available. Now it is mainly used as an added treatment for people with type 1 diabetes on top of standard insulin administration and glucose monitoring. Despite previous studies, the impact of carbohydrate restriction on glycemic control and quality of life is still not clear. Furthermore, few studies exist on carbohydrate restriction in children with type 1 diabetes and combined with the use of hybrid closed-loop insulin delivery. Therefore this study will determine the impact on glycemic control and the feasability of a moderate carbohydrate diet compared to a traditional diet in children (7-17 years) with type 1 diabetes on top of using a hybrid closed-loop system. In this randomized, crossover study, 28 children will follow a moderate carbohydrate diet (four weeks) and a traditional diet (four weeks) in randomized order. With a run-in period (two weeks) prior to the first diet and a wash-out period (six weeks) between the two diets, the children will participate in the study for a total of 16 weeks. The primary endpoint is the difference of time spent in target range (defined as a sensor glucose value between 70 and 180 mg/dL) between the four-week moderate carbohydrate diet and the four-week traditional diet.
CONDITIONS
Official Title
The Impact of a Moderate Carbohydrate Diet in Children With Type 1 Diabetes on Hybrid Closed-loop Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent from both the child/adolescent and parents
- Age between 7 and 17 years at time of consent
- Type 1 diabetes diagnosis for at least 6 months at time of consent
- Use of a hybrid closed-loop system (Medtronic MiniMed 780G, Tandem t:slim X2 Control-IQ, or Mylife Ypsopump with CamAPS algorithm) for at least 3 months at time of consent
- Ability to understand, read, write, and speak Dutch, French, or English at time of consent
You will not qualify if you...
- Age less than 7 or greater than 17 years at time of consent
- Type 1 diabetes diagnosis less than 6 months at time of consent
- Use of advanced hybrid closed-loop system for less than 3 months at time of consent
- Use of any insulin therapy other than the specified advanced hybrid closed-loop systems at time of consent
- Inability to understand, read, write, or speak Dutch, French, or English at time of consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UZ Leuven
Leuven, Vlaams-Brabant, Belgium, 3000
Actively Recruiting
Research Team
K
Kristina Casteels, Prof
CONTACT
L
Laura Valgaerts
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here